Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity

Leuk Res. 2008 Aug;32(8):1321-2. doi: 10.1016/j.leukres.2007.09.009. Epub 2007 Oct 29.

Abstract

As combination of chemotherapy and Gemtuzumab may become a common induction regimen for CD33+ AML patients, there is no report assessing the safety and toxicity of a re-treatment at relapse with such combination in a same patient. Here we describe the case of a 69-year-old patient who achieved a second complete remission with this association without additional toxicity.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aminoglycosides / administration & dosage*
  • Aminoglycosides / adverse effects
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / analysis*
  • Antigens, Differentiation, Myelomonocytic / analysis*
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Feasibility Studies
  • Gemtuzumab
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / immunology
  • Male
  • Remission Induction
  • Sialic Acid Binding Ig-like Lectin 3

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Antineoplastic Agents
  • CD33 protein, human
  • Sialic Acid Binding Ig-like Lectin 3
  • Gemtuzumab